PTC THERAPEUTICS INC (PTCT) Stock Fundamental Analysis
NASDAQ:PTCT - Nasdaq - US69366J2006 - Common Stock - Currency: USD
PTCT gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 556 industry peers in the Biotechnology industry. Both the profitability and the financial health of PTCT get a neutral evaluation. Nothing too spectacular is happening here. PTCT is growing strongly while it is still valued neutral. This is a good combination! With these ratings, PTCT could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
PTCT had positive earnings in the past year.
In the past year PTCT had a positive cash flow from operations.
PTCT had negative earnings in each of the past 5 years.
PTCT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
PTCT has a better Return On Assets (22.40%) than 98.20% of its industry peers.
With an excellent Return On Invested Capital value of 33.50%, PTCT belongs to the best of the industry, outperforming 99.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.4% | ||
| ROE | N/A | ||
| ROIC | 33.5% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 33.55%, PTCT belongs to the best of the industry, outperforming 97.30% of the companies in the same industry.
Looking at the Operating Margin, with a value of 49.27%, PTCT belongs to the top of the industry, outperforming 99.82% of the companies in the same industry.
PTCT has a Gross Margin of 96.87%. This is amongst the best in the industry. PTCT outperforms 96.94% of its industry peers.
In the last couple of years the Gross Margin of PTCT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 49.27% | ||
| PM (TTM) | 33.55% | ||
| GM | 96.87% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PTCT is creating value.
Compared to 1 year ago, PTCT has more shares outstanding
PTCT has more shares outstanding than it did 5 years ago.
PTCT has a worse debt/assets ratio than last year.
2.2 Solvency
PTCT has an Altman-Z score of 1.89. This is not the best score and indicates that PTCT is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of PTCT (1.89) is better than 69.37% of its industry peers.
The Debt to FCF ratio of PTCT is 3.47, which is a good value as it means it would take PTCT, 3.47 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 3.47, PTCT belongs to the best of the industry, outperforming 93.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.47 | ||
| Altman-Z | 1.89 |
ROIC/WACC4.35
WACC7.7%
2.3 Liquidity
A Current Ratio of 3.89 indicates that PTCT has no problem at all paying its short term obligations.
PTCT has a Current ratio (3.89) which is comparable to the rest of the industry.
A Quick Ratio of 3.85 indicates that PTCT has no problem at all paying its short term obligations.
The Quick ratio of PTCT (3.85) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.89 | ||
| Quick Ratio | 3.85 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 189.25% over the past year.
PTCT shows a strong growth in Revenue. In the last year, the Revenue has grown by 91.12%.
Measured over the past years, PTCT shows a very strong growth in Revenue. The Revenue has been growing by 21.32% on average per year.
EPS 1Y (TTM)189.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%936.67%
Revenue 1Y (TTM)91.12%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%459.73%
3.2 Future
PTCT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.94% yearly.
PTCT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.69% yearly.
EPS Next Y199.68%
EPS Next 2Y22.71%
EPS Next 3Y23.7%
EPS Next 5Y21.94%
Revenue Next Year115.86%
Revenue Next 2Y2.59%
Revenue Next 3Y11.35%
Revenue Next 5Y11.69%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 9.38, the valuation of PTCT can be described as reasonable.
Based on the Price/Earnings ratio, PTCT is valued cheaply inside the industry as 97.12% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.45. PTCT is valued rather cheaply when compared to this.
PTCT is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.38 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PTCT is valued cheaply inside the industry as 99.10% of the companies are valued more expensively.
PTCT's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PTCT is cheaper than 98.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.61 | ||
| EV/EBITDA | 4.13 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PTCT's earnings are expected to grow with 23.70% in the coming years.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y22.71%
EPS Next 3Y23.7%
5. Dividend
5.1 Amount
No dividends for PTCT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
49.07
-0.08 (-0.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners100.78%
Inst Owner Change2.67%
Ins Owners0.63%
Ins Owner Change3.97%
Market Cap3.89B
Analysts78.26
Price Target63.78 (29.98%)
Short Float %6.56%
Short Ratio3.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2260.84%
Min EPS beat(2)-221.32%
Max EPS beat(2)4742.99%
EPS beat(4)2
Avg EPS beat(4)1127.12%
Min EPS beat(4)-221.32%
Max EPS beat(4)4742.99%
EPS beat(8)3
Avg EPS beat(8)526.16%
EPS beat(12)3
Avg EPS beat(12)339.46%
EPS beat(16)4
Avg EPS beat(16)251.33%
Revenue beat(2)1
Avg Revenue beat(2)287.62%
Min Revenue beat(2)-10.09%
Max Revenue beat(2)585.33%
Revenue beat(4)2
Avg Revenue beat(4)146.44%
Min Revenue beat(4)-10.09%
Max Revenue beat(4)585.33%
Revenue beat(8)4
Avg Revenue beat(8)74.22%
Revenue beat(12)7
Avg Revenue beat(12)50.19%
Revenue beat(16)10
Avg Revenue beat(16)39.08%
PT rev (1m)0.05%
PT rev (3m)0.49%
EPS NQ rev (1m)0.85%
EPS NQ rev (3m)2.54%
EPS NY rev (1m)22.66%
EPS NY rev (3m)944.1%
Revenue NQ rev (1m)-0.5%
Revenue NQ rev (3m)1.09%
Revenue NY rev (1m)11.27%
Revenue NY rev (3m)107.91%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.38 | ||
| Fwd PE | N/A | ||
| P/S | 2.19 | ||
| P/FCF | 5.61 | ||
| P/OCF | 5.62 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.13 |
EPS(TTM)5.23
EY10.66%
EPS(NY)-2.97
Fwd EYN/A
FCF(TTM)8.74
FCFY17.82%
OCF(TTM)8.73
OCFY17.78%
SpS22.37
BVpS-2.34
TBVpS-4.88
PEG (NY)0.05
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 22.4% | ||
| ROE | N/A | ||
| ROCE | 42.4% | ||
| ROIC | 33.5% | ||
| ROICexc | 2102.85% | ||
| ROICexgc | N/A | ||
| OM | 49.27% | ||
| PM (TTM) | 33.55% | ||
| GM | 96.87% | ||
| FCFM | 39.09% |
ROA(3y)-29.05%
ROA(5y)-26.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y-0.66%
F-Score8
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 3.47 | ||
| Debt/EBITDA | 2.39 | ||
| Cap/Depr | 4.95% | ||
| Cap/Sales | 0.08% | ||
| Interest Coverage | 202.52 | ||
| Cash Conversion | 76.77% | ||
| Profit Quality | 116.5% | ||
| Current Ratio | 3.89 | ||
| Quick Ratio | 3.85 | ||
| Altman-Z | 1.89 |
F-Score8
WACC7.7%
ROIC/WACC4.35
Cap/Depr(3y)15.16%
Cap/Depr(5y)26.1%
Cap/Sales(3y)2.81%
Cap/Sales(5y)3.67%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)189.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%936.67%
EPS Next Y199.68%
EPS Next 2Y22.71%
EPS Next 3Y23.7%
EPS Next 5Y21.94%
Revenue 1Y (TTM)91.12%
Revenue growth 3Y14.42%
Revenue growth 5Y21.32%
Sales Q2Q%459.73%
Revenue Next Year115.86%
Revenue Next 2Y2.59%
Revenue Next 3Y11.35%
Revenue Next 5Y11.69%
EBIT growth 1Y684.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year750.07%
EBIT Next 3Y65.9%
EBIT Next 5YN/A
FCF growth 1Y315.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y339.54%
OCF growth 3YN/A
OCF growth 5YN/A